Alzheimer’s disease is a progressive memory disorder that affects nearly one in three seniors and is on the rise, currently affecting 43 million people worldwide.
Behind the memory impairments, there is a perfect storm of destruction in the brain, stemming in part from accumulations of a protein called tau. Normally a stabilizing structure inside of neurons, tau can accumulate in long tangles that disrupt the ability of neurons to communicate with one another.
University of New Mexico researchers have developed a vaccine that could prevent the formation of the tau tangles and potentially prevent the cognitive decline typically seen in Alzheimer’s patients.
In a paper published last week in NPJ Vaccines, the team reported it had engineered a vaccine using virus-like particles (VLPs, for short) that eliminated the tau tangles in mice that had been bred to develop symptoms like those affecting human Alzheimer’s patients.
“We’re excited by these findings, because they seem to suggest that we can use the body’s own immune system to make antibodies against these tangles, and that these antibodies actually bind and clear these tau tangles,” said Nicole Maphis, a PhD candidate in UNM’s Biomedical Sciences Graduate Program.
Maphis, working in the lab of Kiran Bhaskar, PhD, an associate professor in UNM’s Department of Molecular Genetics & Microbiology, found that when the vaccine was given to mice, they developed antibodies that cleared the tau protein from their brains – and the response lasted for months.
Then, she tested the animals in a battery of maze-like tests. Mice receiving the vaccination performed remarkably better than those that hadn’t. MRI scans showed that the vaccinated animals had less brain shrinkage, suggesting that the vaccine prevented neurons from dying.
Maphis also found significantly fewer tangles in both the cortex and the hippocampus – areas in the brain that are important for learning and memory, and which are destroyed in Alzheimer’s.
“These results confirm that targeting tau tangles using a vaccine intervention could rescue memory impairments and prevent neurons from dying,” Maphis said.
The vaccine was created with help from UNM scientists David Peabody and Bryce Chackerian. The pair helped pioneer the use of VLPs to create vaccines targeting dengue virus, hepatitis B, human papillomavirus and amyloid beta protein (which is also present in the brains of Alzheimer’s patients).
VLPs are derived from viruses that have their genomes removed, leaving only their outer protein shell. Lacking a genome, they’re unable to reproduce, but the body’s immune system still recognizes them as foreign invaders and manufactures antibodies to neutralize the proteins attached to their surface. In this case, a portion of tau protein on the surface of the VLP triggers an immune response, leading to the elimination of the tau tangles.
Going forward, Bhaskar hopes to obtain funding to commercialize this vaccine in order to create an injection that could potentially be tested in human patients. However, moving a drug from bench to bedside can cost millions of dollars and take decades.
By partnering with AgilVax, Inc., a company formed to commercialize the VLP technology, and STC.UNM (UNM’s technology commercialization arm), Bhaskar hopes to receive funding from a federal Small Business Innovation Research grant to help move the research project forward.
Learn more: Memory Preserver
The Latest on: Alzheimer’s vaccine
via Google News
The Latest on: Alzheimer’s vaccine
- Therapeutic Vaccines Market 2018-2026 Clinical Review, Drug Descriptions, Analysis And Synthesis Outlookon October 14, 2019 at 1:46 am
Therapeutic vaccines can be modified as per requirement and used in the treatment of various disorders and diseases such as cancer, HIV infectious diseases, and Alzheimer’s disease. Therapeutic ...
- Seniors News: Alzheimer's Association to host open house to encourage people to become advocateson October 13, 2019 at 6:25 pm
BEDFORD — The Alzheimer’s Association of Massachusetts and New Hampshire is hosting an open ... Most insurances are accepted (subject to deductible). The lower-dose vaccine for those younger than 65 ...
- Fears grow of imminent arrival of 'Aussie flu' threat to elderlyon October 10, 2019 at 6:30 pm
"Seasonal flu vaccine can be given at any stage of pregnancy and also protects the baby, " he added. Jemma Crew Scientists have found a new way to transport medicine into the brain, which they hope ...
- Rebooting Alzheimer’s Research: Gone Are The Days When The Only Suspected Culprits Were Brain Plaques, Tangleson October 8, 2019 at 10:31 am
Since some people die with plenty of amyloid plaques and tangles and never develop dementia, research is expanding to explore the complex disease and how to care for patients. Other public health news ...
- $14m invested to create vaccine for debilitating periodontal gum diseaseon October 6, 2019 at 5:33 pm
A vaccine for periodontal gum disease, which affects a third of all adults globally ... more than 50 per cent of Australians over the age of 65 and is associated with diabetes, heart disease, ...
- THE CANDLE: Vaccines protect from foreign invaders, inner diseaseson October 4, 2019 at 8:55 am
This is proof of concept. Now take some time and Google UB-311, which is in clinical trials as a vaccine against Alzheimer’s. There is also an endobody vaccine for Parkinson’s (UB-312), one for ...
- It’s News Roundup Time! Cheap Vaccines, Genomics and More …on October 4, 2019 at 6:53 am
The US National Institute on Aging has announced a five-year grant of €34M ($37.5M) to fund the launch of the Open-AD Drug Discovery Center, a network of US and European collaborations aimed to ...
- Charles River Laboratories Joins Dementia Consortium, Reaffirms Commitment to Neuroscience Researchon October 3, 2019 at 6:08 pm
We are proud to be part of the important work they’re doing” –Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine ...
- Alzheimer's Disease Treatment Market is expected to grow at a CAGR of 12.1% during 2018 to 2025on October 2, 2019 at 6:34 am
For Instance, In January 2015, Johnson & Johnson partnered with Swiss biopharma AC Immune to develop a therapeutic vaccine for the development of anti-tau Alzheimer's vaccine Key player's profiles in ...
- Slovakian biotech firm in tentative Alzheimer's drug hopeon September 9, 2019 at 7:00 am
FRANKFURT, Sept 9 (Reuters) - An Alzheimer’s vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, in a rare step forward in the fight ...
via Bing News